Full-Time

Senior/Principal Research Associate

In Vivo

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

201-500 employees

Develops genetic medicines for neurological diseases

Biotechnology
Healthcare

Senior, Expert

Lexington, MA, USA

Category
Lab & Research
Medical Research
Required Skills
Data Analysis

You match the following Voyager Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • A Master’s degree with a minimum of 6 years of experience or a Bachelor’s Degree with a minimum of 8 years of experience is required
  • A minimum of 6 years of hands-on experience with performing test article administration in rodent (mouse and rat) is required
  • Experience in neuroscience is required
  • Technical proficiency with a wide variety of rodent in vivo pharmacology skills (IV, IP, stereotactic delivery) is required
  • Outstanding problem-solving skills and ability to multi-task is required
  • Self-motivated, able to work independently, highly organized with strong attention to detail is required
Responsibilities
  • The individual will be responsible for experimental design, execution and data analysis for research studies supporting platform and discovery research
  • Design and hands-on execute rodent in vivo experiments including experiments in animal models of neurodegenerative disease
  • Performing test article dosing via various administration routes (e.g. IV, brain stereotactic infusions), brain and tissue collection, and downstream analysis (e.g. RT-qPCR, bDNA, western blot and ELISA)
  • Performing data analyses and delivering data presentation to teams
  • Ensuring maintenance of industry-quality records and proper documentation
  • Monitor health, perform behavioral assessments and tissue/blood collection
Desired Qualifications
  • Conducting ex vivo tissue analysis (i.e. Digital ELISA, RT-qPCR, etc) preferred

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary platform that utilizes adeno-associated virus (AAV) capsids to deliver genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed to address severe neurological conditions, and they emphasize collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from these debilitating diseases.

Company Size

201-500

Company Stage

IPO

Total Funding

$102.1M

Headquarters

Cambridge, Massachusetts

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Novartis could accelerate pipeline and expand market reach.
  • Electric pulse technology may enhance gene therapy delivery efficiency and reduce costs.
  • FDA approval of gene therapy for sickle cell disease may benefit Voyager's initiatives.

What critics are saying

  • Dependency on Novartis collaboration may affect Voyager's R&D autonomy.
  • Leadership changes may indicate potential instability or strategic shifts.
  • Reliance on milestone payments could create financial uncertainty if timelines are delayed.

What makes Voyager Therapeutics unique

  • Voyager's TRACER™ platform enhances CNS drug delivery by penetrating the blood-brain barrier.
  • The company focuses on gene therapies for CNS diseases like ALS and Parkinson's.
  • Voyager's proprietary AAV capsid discovery platform shows promise in preclinical studies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

7%
SMA News Today
Jan 3rd, 2025
Top 10 SMA news stories of 2024

At the start of 2024, Voyager Therapeutics announced that it would collaborate with Novartis to discover and develop next-generation gene therapies for SMA and other neurologic conditions.

MarketBeat
Sep 24th, 2024
Great Point Partners LLC Invests $12.67 Million in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Great Point Partners LLC invests $12.67 million in Voyager Therapeutics, Inc. (NASDAQ:VYGR).

CityBiz
Jun 13th, 2024
Voyager Therapeutics Appoints Nathan Jorgensen as Chief Financial Officer

Voyager Therapeutics appoints Nathan Jorgensen as Chief Financial Officer.

Securities.io
May 7th, 2024
Super Charging Gene Therapy With Electric Pulses

Improving Gene TherapyIn December 2023, the FDA made history by approving the first human gene therapy for sickle cell disease. This was quite a revolution and opened the way for much more gene therapy for other incurable diseases.One difficulty in all gene therapy procedures is getting enough of the intended genetic material delivered into the target cells. This can cause multiple issues, from too low gene modification to be efficient as a medicine to un-targeted cells being modified or immune reactions and side effects from too concentrated a dose. And, of course, using more than needed gene editing medicine is expensive.Luckily, researchers might have found a way to solve this issue, using electric pulses to boost the efficiency of gene transformation 40 times.Electricity For Gene EditingUsing electricity for gene modification is not really a new concept in itself, with electroporation a very ancient method used to create GMOs. However, in the case of this method, the damage inflicted on the cells by the very high voltage makes it only fit for modifying cell culture, bacteria, or plants, and not the gene inside a living animal or human.What the researchers at the University of Wisconsin–Madison have discovered is that gene therapies can be improved with a short pulse of electricity instead. This was done in collaboration between University of Wisconsin–Madison researchers ( Susan Hagness and John Booske and PhD student Yizhou Yao) and Hans Sollinger, a world-renowned transplant surgeon.Contrary to the more brutal electroporation method, the electric pulses are very quick, only 80 milliseconds long

BioSpace
May 6th, 2024
Voyager Therapeutics Announces First Quarter 2024 Conference Call And Webcast

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI1f6af80e7a614ca7925cbad2f35a55c6. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion

ETF Daily News
Apr 18th, 2024
Cornercap Investment Counsel Inc. Invests $196,000 in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Cornercap Investment Counsel Inc. invests $196,000 in Voyager Therapeutics, Inc. (NASDAQ:VYGR).

BioSpace
Apr 16th, 2024
Voyager Therapeutics Announces Selection Of Development Candidate For Gba1 Program In Collaboration With Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform. The companies expect to file an Investigational New Drug (IND) application with the FDA for the program in 2025.Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the second quarter of 2024. Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.“The nomination of this development candidate in the GBA1 program, following the recent nomination of a development candidate in the Friedreich’s ataxia program, demonstrates the productivity of the collaboration between Voyager and Neurocrine to advance gene therapies for neurological diseases,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager

Investing.com
Mar 13th, 2024
Voyager Therapeutics names ex-Biogen VP as new Chief Medical Officer

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a company focusing on neurogenetic medicine development, announced the appointment of Toby Ferguson, M.D., Ph.D., as its new Chief Medical Officer (CMO).

Life Care News
Jan 5th, 2024
Voyager Therapeutics Announces Pricing of Public Offering - LifeCare News

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who…

Investopedia
Jan 2nd, 2024
Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments

Voyager Therapeutics Inc. and Novartis AG signed a licensing agreement to develop treatments for neurological diseases.